Navigation Links
Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research

Gavin MacBeath, Ph.D., will be responsible for leading the MM-121 research team through Development and creating the Company’s general strategy for predictive medicine.

(PRWEB) May 26, 2010 -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer and inflammation, today announced that Gavin MacBeath, Ph.D., one of the Company’s six founders, has been hired as a Senior Director and the Head of Translational Research.

“Gavin joining Merrimack underscores the pivotal next step of our vision to extend Network Biology beyond discovery research and apply it to clinical development of drugs. We believe translational science anchored in Network Biology is a key recipe for developing next generation drugs as we better characterize the underlying tumor biology for the patients we are treating,” says Clet Niyikiza, Ph.D., Merrimack’s Senior Vice President of Development.

Since Merrimack was founded in 2000, Dr. MacBeath has served on the faculty in the Department of Chemistry and Chemical Biology at Harvard University, where he has focused on developing technology that facilitates basic research in the area of systems biology. In this new position, Dr. MacBeath will be responsible for leading the MM-121 research team through Development and creating the Company’s general strategy for predictive medicine.

“Merrimack provides the resources and environment needed to address what I believe is the biggest challenge in biomedical research for the twenty-first century - the problem of matching patients to therapies” said Dr. MacBeath. “Research and development at Merrimack over the coming years will determine how important Network Biology is in the context of co-developing drugs and companion diagnostics that identify which patients will respond most effectively.”

Dr. MacBeath will continue to direct a research lab at Harvard Medical School and will serve as a bridge between Merrimack and Harvard’s academic community. Dr. MacBeath received his Bachelors of Science at the University of Manitoba and his doctorate in Macromolecular and Cellular Structure and Chemistry at the Scripps Research Institute.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma(dot)com; Betsy Raymond Stevenson, 860-984-1424, RaymondStevenson Healthcare Comms betsy(at)raymondstevenson(dot)com


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
2. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
3. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
4. ARUP Laboratories CEO and Co-Founder Announces Retirement
6. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Scripps Research Institute Highlights Groundbreaking Work of aTyr Pharma Scientific Co-Founder
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
Post Your Comments:
Related Image:
Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research 
(Date:10/13/2015)... , Oct. 13, 2015  Generex Biotechnology Corporation ( ... into a non-binding Letter of Intent (LOI) with MediTemp Ltd. ... developed a proprietary cooling technology designed to improve sperm quality ... the United States and three million men in ... and 44 diagnosed as infertile.  For 42% of those men, ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... (HIFU) technologies, announced today that it received de novo clearance from the U.S. ... U.S. for the ablation of prostate tissue. Sonablate® is the first High Intensity ...
(Date:10/13/2015)... the United States , Canada ... all new cases of kidney cancer.   --> ... Europe .  PRCC represents about 14% of all ... MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ... completed enrolment in a global Phase II study of savolitinib (AZD6094), ...
(Date:10/12/2015)... MARIETTA, Ga. , Oct.12, 2015  MiMedx Group, ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and ... tam complaint which had been filed against the Company ... Parker H. Petit , Chairman and CEO, stated, "As ...
Breaking Biology Technology:
(Date:10/6/2015)... 2015 Track Group, Inc. (OTCQX: TRCK), a ... signed a contract with the Virginia Department of Corrections ... of sentences under the Department,s oversight. Derek ... contract with the Virginia DOC will expand our footprint ... our position as a trusted leader in offender electronic ...
(Date:10/2/2015)... ) has ... Law Using Biometrics" report to their offering. ... addition of the "Enforcing the Law Using ... Research and Markets ( ) has ... Law Using Biometrics" report to their offering. ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
Breaking Biology News(10 mins):